Drug intelligence / Profile preview

HK010

Development stage: Unknown
Lead developer: Hefei HankeMab Biotechnology
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HK010 is a recombinant humanized bispecific antibody targeting both Programmed Death-Ligand 1 (PD-L1) and Vascular Endothelial Growth Factor (VEGF). Developed by Hefei HanKeMab Biotechnology and Anhui Anke Biotechnology, it is designed to simultaneously block the PD-1/PD-L1 immunosuppressive pathway and inhibit VEGF-mediated angiogenesis within the tumor microenvironment. This dual mechanism aims to enhance anti-tumor immune responses while normalizing tumor vasculature, potentially offering synergistic efficacy over monotherapies. It is currently being evaluated in clinical trials for advanced solid tumors, with a focus on hepatocellular carcinoma and extrapulmonary neuroendocrine carcinoma.

Other names: Anti-PD-L1/VEGF bispecific antibody

Targets

CD274 (Programmed cell death protein 1 ligand 1)TNFRSF9 (CD137 extracellular domain)

Beyond the preview

Go deeper on HK010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HK010.

Explore the full profile